Literature DB >> 33832361

Uncoupled bone remodeling is characteristic of bone damage in premenopausal women with new-onset systemic lupus erythematosus.

Li Zhu1, Jing Zhang1, Jing Wang1, Xiaohong Lv1, Dan Pu1, Yanhua Wang1, Qian Men1, Lan He1.   

Abstract

OBJECTIVE: To investigate the mechanism underlying systemic lupus erythematosus (SLE)-related bone loss by evaluating the bone mineral density (BMD) and bone turnover markers (BTMs) in premenopausal patients with new-onset SLE without any treatment.
METHODS: BMD and BTMs of 106 premenopausal patients with new-onset SLE and 64 gender-, age- and body mass index (BMI)-matched healthy controls were analyzed. BMD was determined using dual energy X-ray absorptiometry (DXA). Serum BTMs were measured.
RESULTS: Hip and lumbar spine BMD in premenopausal patients with new-onset SLE was significantly decreased compared with healthy controls. Higher rate of osteoporosis was observed in new-onset SLE patients (25% vs. 1%). Moreover, uncoupled bone remodeling evidenced by an increase in bone resorption marker β-CTX (685.9 ± 709.6 pg/mL vs. 395.4 ± 326.0 pg/mL, P < 0.05) and decrease in bone formation markers PINP (37.4 ± 33.0 ng/mL vs. 46.1 ± 20.9 ng/mL, P < 0.05) and OC (11.4 ± 9.8 ng/mL vs. 18.2 ± 8.6 ng/mL, P < 0.05) was observed in premenopausal patients with new-onset SLE compared with healthy controls. Univariate correlation analyses showed negative correlations between OC and SLE Disease Activity Index (SLEDAI), and positive correlations between β-CTX and SLEDAI. SLE patients positive for dsDNA, nucleosome showed lower OC and higher β-CTX.
CONCLUSION: Premenopausal patients with new-onset SLE had decreased BMD and abnormal bone metabolism with increased β-CTX and decreased OC and P1NP levels, indicating uncoupled bone remodeling in new-onset SLE patients. Disease activity and abnormal immunity, especially the amount of antibodies in SLE patients, were strongly associated with abnormality of bone metabolism.

Entities:  

Keywords:  Premenopausal systemic lupus erythematosus; bone formation; bone mineral density; bone resorption

Year:  2021        PMID: 33832361     DOI: 10.1177/09612033211005067

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  3 in total

Review 1.  Therapeutic Treatments for Osteoporosis-Which Combination of Pills Is the Best among the Bad?

Authors:  Christian Horst Tonk; Sarah Hani Shoushrah; Patrick Babczyk; Basma El Khaldi-Hansen; Margit Schulze; Monika Herten; Edda Tobiasch
Journal:  Int J Mol Sci       Date:  2022-01-26       Impact factor: 5.923

2.  A tissue-selective estrogen complex as treatment of osteoporosis in experimental lupus.

Authors:  Jauquline Nordqvist; Cecilia Engdahl; Julia M Scheffler; Priti Gupta; Karin L Gustafsson; Marie K Lagerquist; Hans Carlsten; Ulrika Islander
Journal:  Lupus       Date:  2022-01-21       Impact factor: 2.911

Review 3.  Role of Exosomal MicroRNAs and Their Crosstalk with Oxidative Stress in the Pathogenesis of Osteoporosis.

Authors:  Jun Lu; Yan Zhang; Jinqi Liang; Jiayu Diao; Peilong Liu; Hongmou Zhao
Journal:  Oxid Med Cell Longev       Date:  2021-07-19       Impact factor: 6.543

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.